Market Analysis and Insights: Global Solid Tumor Drug Market
Due to the COVID-19 pandemic, the global Solid Tumor Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Small Molecules accounting for % of the Solid Tumor Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Oncology segment is altered to an % CAGR throughout this forecast period.
China Solid Tumor Drug market size is valued at US$ million in 2021, while the US and Europe Solid Tumor Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Solid Tumor Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Solid Tumor Drug include AstraZeneca, Biogen, Baxter, Celgene Corporation, Abbott Laboratories, Pfizer Inc, Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company and GlaxoSmithKline plc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Solid Tumor Drug Scope and Segment
Solid Tumor Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Solid Tumor Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Small Molecules
Biologics
Segment by Application
Oncology
Neurology
Radiology
Others
By Company
AstraZeneca
Biogen
Baxter
Celgene Corporation
Abbott Laboratories
Pfizer Inc
Amgen Limited & Amgen Ireland Limited
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Johnson & Johnson
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE